ATE389658T1 - Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren - Google Patents

Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren

Info

Publication number
ATE389658T1
ATE389658T1 AT03766152T AT03766152T ATE389658T1 AT E389658 T1 ATE389658 T1 AT E389658T1 AT 03766152 T AT03766152 T AT 03766152T AT 03766152 T AT03766152 T AT 03766152T AT E389658 T1 ATE389658 T1 AT E389658T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
pyrazole derivatives
heterocyclic condensed
condensed pyrazole
heterocyclic
Prior art date
Application number
AT03766152T
Other languages
English (en)
Inventor
Roberto Tonani
Simona Bindi
Daniele Fancelli
Valeria Pittala
Mario Varasi
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE389658T1 publication Critical patent/ATE389658T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03766152T 2002-07-25 2003-07-11 Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren ATE389658T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39812102P 2002-07-25 2002-07-25

Publications (1)

Publication Number Publication Date
ATE389658T1 true ATE389658T1 (de) 2008-04-15

Family

ID=31495717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766152T ATE389658T1 (de) 2002-07-25 2003-07-11 Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren

Country Status (13)

Country Link
US (3) US7541378B2 (de)
EP (1) EP1530573B1 (de)
JP (1) JP4533138B2 (de)
AR (1) AR040520A1 (de)
AT (1) ATE389658T1 (de)
AU (1) AU2003250040A1 (de)
BR (1) BR0312961A (de)
CA (1) CA2493680C (de)
DE (1) DE60319836T2 (de)
ES (1) ES2303601T3 (de)
MX (1) MXPA05000946A (de)
TW (1) TW200413383A (de)
WO (1) WO2004013146A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200526204A (en) * 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878442B1 (fr) * 2004-11-29 2008-10-24 Aventis Pharma Sa THIENO(2,3-c)PYRAZOLES SUBSTITUES, PROCEDE DE PREPARATION, COMPOSITIONS LES CONTENANT ET UTILISATION
US7485661B2 (en) * 2005-01-18 2009-02-03 Pfizer Italia S.R.L. Heterobicyclic pyrazole derivatives as kinase inhibitors
FR2882751B1 (fr) 2005-03-04 2007-09-14 Aventis Pharma Sa Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
US7943654B2 (en) 2005-07-19 2011-05-17 Nerviano Medical Sciences S.R.L. 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
EP1942885A1 (de) * 2005-10-06 2008-07-16 Merck Sharp & Dohme Ltd. Verwendung von kondensierten pyrrolcarbonsäuren zur behandlung von neurodegenerativen und psychiatrischen erkrankungen als d-aminosäure-oxidase-hemmer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2904626B1 (fr) 2006-08-03 2008-09-19 Sanofi Aventis Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711592B2 (en) * 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
KR100904157B1 (ko) * 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
JP2004509891A (ja) * 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
TW200526204A (en) * 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors

Also Published As

Publication number Publication date
JP4533138B2 (ja) 2010-09-01
CA2493680C (en) 2010-09-07
DE60319836D1 (de) 2008-04-30
TW200413383A (en) 2004-08-01
US7786048B2 (en) 2010-08-31
AU2003250040A1 (en) 2004-02-23
BR0312961A (pt) 2005-06-14
ES2303601T3 (es) 2008-08-16
US20060122249A1 (en) 2006-06-08
MXPA05000946A (es) 2005-05-16
AR040520A1 (es) 2005-04-06
US20090233813A1 (en) 2009-09-17
US20100286223A1 (en) 2010-11-11
DE60319836T2 (de) 2009-05-07
JP2005537288A (ja) 2005-12-08
EP1530573B1 (de) 2008-03-19
US7541378B2 (en) 2009-06-02
WO2004013146A1 (en) 2004-02-12
US8017643B2 (en) 2011-09-13
EP1530573A1 (de) 2005-05-18
CA2493680A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
IS7599A (is) Heterósýklískir kínasatálmar
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE455546T1 (de) Aminotriazol-verbindungen als proteinkinase- hemmer
DE60315516D1 (de) Pyridazinon-derivate als cdk2-hemmer
ATE318814T1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
DK1549652T3 (da) Kondenserede azolpyrimidinderivater
DE60304911D1 (de) Xanthin-Derivate als DPP-IV-Inhibitoren
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE326462T1 (de) Pyrazolverbindungen als protein-kinase- inhibitoren
ATE346064T1 (de) Pyrazolverbindungen als protein-kinasehemmer
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE444292T1 (de) Pyrazolderivate als faktor-xa-inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DE60319836D1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties